Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Purchased by QRG Capital Management Inc.

QRG Capital Management Inc. increased its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 10.9% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 13,050 shares of the company's stock after acquiring an additional 1,283 shares during the period. QRG Capital Management Inc.'s holdings in Medpace were worth $3,976,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Sone Capital Management LLC acquired a new position in Medpace during the 4th quarter worth about $1,318,000. Sanctuary Advisors LLC lifted its stake in Medpace by 20.5% during the 4th quarter. Sanctuary Advisors LLC now owns 4,964 shares of the company's stock worth $1,738,000 after acquiring an additional 844 shares in the last quarter. Truist Financial Corp lifted its stake in Medpace by 166.2% during the 4th quarter. Truist Financial Corp now owns 10,277 shares of the company's stock worth $3,414,000 after acquiring an additional 6,417 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Medpace by 1.1% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 201,046 shares of the company's stock worth $66,794,000 after acquiring an additional 2,142 shares in the last quarter. Finally, Orion Portfolio Solutions LLC lifted its stake in Medpace by 347.6% during the 4th quarter. Orion Portfolio Solutions LLC now owns 4,248 shares of the company's stock worth $1,411,000 after acquiring an additional 3,299 shares in the last quarter. Institutional investors and hedge funds own 77.98% of the company's stock.

Medpace Trading Up 1.6%

Medpace stock opened at $302.69 on Thursday. The stock has a 50 day moving average of $299.23 and a two-hundred day moving average of $321.96. The stock has a market capitalization of $8.70 billion, a price-to-earnings ratio of 23.11, a PEG ratio of 5.38 and a beta of 1.47. Medpace Holdings, Inc. has a twelve month low of $250.05 and a twelve month high of $459.77.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its quarterly earnings results on Monday, April 21st. The company reported $3.67 EPS for the quarter, beating the consensus estimate of $3.06 by $0.61. The business had revenue of $558.57 million during the quarter, compared to analysts' expectations of $528.38 million. Medpace had a return on equity of 54.36% and a net margin of 19.31%. During the same period last year, the firm earned $3.20 EPS. Equities analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. Leerink Partnrs upgraded Medpace to a "hold" rating in a report on Monday, March 24th. Leerink Partners assumed coverage on Medpace in a report on Monday, March 24th. They set a "market perform" rating and a $330.00 price target on the stock. Mizuho cut their price target on Medpace from $400.00 to $355.00 and set an "outperform" rating on the stock in a report on Wednesday, April 9th. Truist Financial dropped their price objective on Medpace from $333.00 to $300.00 and set a "hold" rating on the stock in a report on Wednesday, April 23rd. Finally, William Blair reissued a "market perform" rating on shares of Medpace in a research report on Tuesday, April 22nd. Eleven equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Hold" and a consensus target price of $349.30.

Insider Activity at Medpace

In other Medpace news, Director Fred B. Davenport, Jr. sold 1,712 shares of the firm's stock in a transaction on Thursday, April 24th. The stock was sold at an average price of $301.82, for a total transaction of $516,715.84. Following the completion of the transaction, the director now owns 2,998 shares of the company's stock, valued at approximately $904,856.36. This trade represents a 36.35% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 20.30% of the stock is currently owned by company insiders.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.